1. Pink Sheet
  2. >>Vaccines

Novavax EUA Justified By US FDA With Claims Of COVID Vaccine Supply Constraints

 
• By Derrick Gingery

The agency also includes a myocarditis warning in the fact sheet for the first protein-based COVID-19 vaccine to reach the US market.

Novavax COVID-19 vaccine
Novavax received an EUA for only a primary vaccine series, which is two shots three weeks apart. • Source: Shutterstock

The US Food and Drug Administration continues to argue that supply problems necessitate authorization of another COVID-19 vaccine, in this case one from Novavax, Inc., even though concerns persist that available doses of other vaccines are going unused.

FDA officials on 13 July granted the long-expected emergency use authorization for Novavax’s vaccine in adults 18 and older

More from Vaccines

More from Pink Sheet